An Open-Label Phase Ib Dose-Escalation Study of TRC105...

Clinical Cancer Research 2014 / 12 Vol. 20; Iss. 23

An Open-Label Phase Ib Dose-Escalation Study of TRC105 (Anti-Endoglin Antibody) with Bevacizumab in Patients with Advanced Cancer

Gordon, M. S., Robert, F., Matei, D., Mendelson, D. S., Goldman, J. W., Chiorean, E. G., Strother, R. M., Seon, B. K., Figg, W. D., Peer, C. J., Alvarez, D., Adams, B. J., Theuer, C. P., Rosen, L. S.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
20
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-14-1143
Date:
December, 2014
File:
PDF, 253 KB
english, 2014
Conversion to is in progress
Conversion to is failed